Eritrea
Tuberculosis profile
| High HIV burden |
Population  2012 6.1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.28 (0.19–0.4) 4.6 (3–6.5)
Mortality (HIV+TB only) 0.24 (0.19–0.31) 3.9 (3.1–5)
Prevalence  (includes HIV+TB) 9.3 (3.5–18) 152 (56–294)
Incidence  (includes HIV+TB) 5.7 (3.8–8) 93 (62–131)
Incidence (HIV+TB only) 0.73 (0.49–1) 12 (7.9–17)
Case detection, all forms (%) 55 (39–83)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 779 (26) Relapse 117 (51)
Smear-negative 1 013 (33) Treatment after failure 22 (10)
Smear-unknown / not done 141 (5) Treatment after default 10 (4)
Extrapulmonary 1 093 (36) Other 79 (35)
Other 0 (0)      
Total new 3 026   Total retreatment 228  
           
Other (history unknown) 0        
Total new and relapse 3 143   Total cases notified 3 254  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.3    
Age < 15 6 491 383
Laboratories 2012
Smear (per 100 000 population) 1.3
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 87   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 71  
Retreatment 69  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 913 (59)
HIV-positive TB patients 164 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
35 (2–66) 44 (17–71)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB      
Laboratory-confirmed MDR-TB cases     0
Patients started on MDR-TB treatment     23
Financing TB control 2013
National TB programme budget (US$ millions) 3.8
% Funded domestically <1%
% Funded internationally 99%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-25 Data: www.who.int/tb/data